COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study

Francisco Tsz Tsun Lai; Vincent Ka Chun Yan; Eric Yuk Fai Wan; Cheyenne I. Ying Chan; Cuiling Wei; Franco Wing Tak Cheng; Celine Sze Ling Chui; Xue Li; Carlos King Ho Wong; Ching Lung Cheung; Ian Chi Kei Wong; Esther Wai Yin Chan

doi:10.1016/j.isci.2024.109428

COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study

Francisco Tsz Tsun Lai
, Vincent Ka Chun Yan
, Eric Yuk Fai Wan
, Cheyenne I. Ying Chan
, Cuiling Wei
, Franco Wing Tak Cheng
, Celine Sze Ling Chui
, Xue Li
, Carlos King Ho Wong
, Ching Lung Cheung
, Ian Chi Kei Wong
, Esther Wai Yin Chan

Aston Pharmacy School

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

6 Downloads (Pure)

Abstract

Multimorbidity entails a higher risk of SARS-CoV-2 infection and COVID-19 complications. We examined vaccine effectiveness (VE) stratified by multimorbidity using a case-control study of territory-wide electronic health records in Hong Kong. Cases of infection (testing positive), hospitalization, and mortality were identified from January to March 2022. Controls were matched by age, sex, outpatient attendance/hospitalization date, and Charlson Comorbidity Index. We demonstrated a consistently good VE among people with increased multimorbidity burden; even more so than among those with minimal such burden. There was also a significantly greater VE after a third dose of BNT162b2 or CoronaVac against infection. The difference in VE between those with multimorbidity and those without was less pronounced for hospitalization, and such difference for COVID-19-related mortality was negligible. In conclusion, VE of both examined vaccines against SARS-CoV-2 infection among people with more complex multimorbidity burden is significant. Further vaccine roll-out should prioritize people with multimorbidity.

Original language	English
Article number	109428
Number of pages	12
Journal	iScience
Volume	27
Issue number	4
Early online date	4 Mar 2024
DOIs	https://doi.org/10.1016/j.isci.2024.109428
Publication status	Published - 19 Apr 2024

Bibliographical note

Funding

This work was funded by a research grant from the Food and Health Bureau ; HMRF Research on COVID-19 , The Government of the Hong Kong Special Administrative Region ( Principal Investigator (WP2): E.W.Y.C. ; Principal Applicant PL ; Ref: COVID1903011 ). F.T.T.L. and I.C.K.W. are partially supported by the Laboratory of Data Discovery for Health (D24H) funded by the AIR@InnoHK administered by Innovation and Technology Commission . The funders played no role in the design, conduct and dissemination of the study.

Access to Document

10.1016/j.isci.2024.109428Licence: CC BY-NC 4.0

FTT Lai et al_COVID-19 vaccine effectiveness against the Omicron variant_territory wide
Copyright © 2024 The Authors. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/).
Final published version, 3.13 MBLicence: CC BY-NC 4.0

Cite this

Lai, F. T. T., Yan, V. K. C., Wan, E. Y. F., Chan, C. I. Y., Wei, C., Cheng, F. W. T., Chui, C. S. L., Li, X., Wong, C. K. H., Cheung, C. L., Wong, I. C. K., & Chan, E. W. Y. (2024). COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study. iScience, 27(4), Article 109428. https://doi.org/10.1016/j.isci.2024.109428

@article{7c4d3a27190f467cb6b687a77a174fa7,

title = "COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study",

abstract = "Multimorbidity entails a higher risk of SARS-CoV-2 infection and COVID-19 complications. We examined vaccine effectiveness (VE) stratified by multimorbidity using a case-control study of territory-wide electronic health records in Hong Kong. Cases of infection (testing positive), hospitalization, and mortality were identified from January to March 2022. Controls were matched by age, sex, outpatient attendance/hospitalization date, and Charlson Comorbidity Index. We demonstrated a consistently good VE among people with increased multimorbidity burden; even more so than among those with minimal such burden. There was also a significantly greater VE after a third dose of BNT162b2 or CoronaVac against infection. The difference in VE between those with multimorbidity and those without was less pronounced for hospitalization, and such difference for COVID-19-related mortality was negligible. In conclusion, VE of both examined vaccines against SARS-CoV-2 infection among people with more complex multimorbidity burden is significant. Further vaccine roll-out should prioritize people with multimorbidity.",

author = "Lai, \{Francisco Tsz Tsun\} and Yan, \{Vincent Ka Chun\} and Wan, \{Eric Yuk Fai\} and Chan, \{Cheyenne I. Ying\} and Cuiling Wei and Cheng, \{Franco Wing Tak\} and Chui, \{Celine Sze Ling\} and Xue Li and Wong, \{Carlos King Ho\} and Cheung, \{Ching Lung\} and Wong, \{Ian Chi Kei\} and Chan, \{Esther Wai Yin\}",

note = "Copyright {\textcopyright} 2024 The Authors. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/). ",

year = "2024",

month = apr,

day = "19",

doi = "10.1016/j.isci.2024.109428",

language = "English",

volume = "27",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study

AU - Lai, Francisco Tsz Tsun

AU - Yan, Vincent Ka Chun

AU - Wan, Eric Yuk Fai

AU - Chan, Cheyenne I. Ying

AU - Wei, Cuiling

AU - Cheng, Franco Wing Tak

AU - Chui, Celine Sze Ling

AU - Li, Xue

AU - Wong, Carlos King Ho

AU - Cheung, Ching Lung

AU - Wong, Ian Chi Kei

AU - Chan, Esther Wai Yin

PY - 2024/4/19

Y1 - 2024/4/19

N2 - Multimorbidity entails a higher risk of SARS-CoV-2 infection and COVID-19 complications. We examined vaccine effectiveness (VE) stratified by multimorbidity using a case-control study of territory-wide electronic health records in Hong Kong. Cases of infection (testing positive), hospitalization, and mortality were identified from January to March 2022. Controls were matched by age, sex, outpatient attendance/hospitalization date, and Charlson Comorbidity Index. We demonstrated a consistently good VE among people with increased multimorbidity burden; even more so than among those with minimal such burden. There was also a significantly greater VE after a third dose of BNT162b2 or CoronaVac against infection. The difference in VE between those with multimorbidity and those without was less pronounced for hospitalization, and such difference for COVID-19-related mortality was negligible. In conclusion, VE of both examined vaccines against SARS-CoV-2 infection among people with more complex multimorbidity burden is significant. Further vaccine roll-out should prioritize people with multimorbidity.

AB - Multimorbidity entails a higher risk of SARS-CoV-2 infection and COVID-19 complications. We examined vaccine effectiveness (VE) stratified by multimorbidity using a case-control study of territory-wide electronic health records in Hong Kong. Cases of infection (testing positive), hospitalization, and mortality were identified from January to March 2022. Controls were matched by age, sex, outpatient attendance/hospitalization date, and Charlson Comorbidity Index. We demonstrated a consistently good VE among people with increased multimorbidity burden; even more so than among those with minimal such burden. There was also a significantly greater VE after a third dose of BNT162b2 or CoronaVac against infection. The difference in VE between those with multimorbidity and those without was less pronounced for hospitalization, and such difference for COVID-19-related mortality was negligible. In conclusion, VE of both examined vaccines against SARS-CoV-2 infection among people with more complex multimorbidity burden is significant. Further vaccine roll-out should prioritize people with multimorbidity.

UR - https://www.cell.com/iscience/fulltext/S2589-0042(24)00649-7?_returnURL=https%253A%252F%252Flinkinghub.elsevier.com%252Fretrieve%252Fpii%252FS2589004224006497

UR - https://www.scopus.com/pages/publications/85188077376

U2 - 10.1016/j.isci.2024.109428

DO - 10.1016/j.isci.2024.109428

M3 - Article

C2 - 38544567

SN - 2589-0042

VL - 27

JO - iScience

JF - iScience

IS - 4

M1 - 109428

ER -

COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study

Abstract

Bibliographical note

Funding

Access to Document

Other files and links

Fingerprint

Cite this